Clinical Trial Update: Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHJ002 Ophthalmic Solution for corneal erosion in Sjögren's syndrome patients has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Erosion
• Sjögren Syndrome

Drugs mentioned

• SHJ002 Ophthalmic Solution

Snippet

Sponsor: Sunhawk Vision Biotech, Inc. | Conditions: Corneal Erosion | Phase 2 | Status: COMPLETED | Results posted: 2025-08-22